As a new-generation orexin receptor antagonist, daridorexant (Quviviq) improves sleep quality through a unique mechanism, providing a new treatment option for patients with insomnia.

How Effective is Daridorexant (Quviviq) in Treatment?

Key Therapeutic Effects

By selectively blocking orexin receptors (OX1R and OX2R), daridorexant inhibits wakefulness-promoting neural signals in the brain, thereby helping patients achieve a natural sleep state.

Improving sleep initiation: Shortens the time required to fall asleep and alleviates sleep-onset insomnia.

Maintaining sleep continuity: Reduces the frequency and duration of nighttime awakenings, enhancing sleep integrity.

Suitable Populations and Contraindications for Daridorexant (Quviviq)

Target Patient Groups

Patients diagnosed with sleep-onset insomnia and/or sleep-maintenance insomnia.

Patients in need of long-term treatment who have concerns about traditional sedative medications.

Patients with mild to moderate hepatic impairment (dosage adjustment required) or renal impairment (no dosage adjustment required).

Contraindications and Precautions for Use

Absolute contraindications: Contraindicated in patients with narcolepsy (may exacerbate symptoms).

Relative precautions for use: Not recommended for patients with severe hepatic impairment (Child-Pugh score ≥ 10).

Patients with concurrent moderate to severe respiratory dysfunction (e.g., untreated obstructive sleep apnea, severe COPD).

Patients with a history of depression or suicidal tendencies require close monitoring of emotional changes.

Medication Monitoring for Daridorexant (Quviviq)

Dosage and Administration Regimen

Routine dosage: Take orally once daily at night, within 30 minutes before bedtime. Ensure there is at least 7 hours of potential sleep time after administration.

Special adjustments: When used in combination with moderate CYP3A4 inhibitors, the daily dosage should not exceed 25mg.

Avoid concurrent use with strong CYP3A4 inhibitors or inducers.

Adverse Reaction Monitoring

Impact on daytime function: May cause decreased alertness; avoid driving or operating precision equipment during treatment.

Complex sleep behaviors: Unconscious activities such as sleepwalking and sleep-eating. Discontinue the medication immediately if such behaviors occur.

Worsening of mental symptoms: Prompt intervention is required if depression or suicidal ideation worsens.

Long-Term Management Recommendations

Regular follow-up: Elderly patients and those taking concurrent medications should be monitored for fall risk and drug interactions.

Pregnancy and lactation: The risks and benefits must be weighed when using the medication in pregnant women; it is not recommended for use during lactation.